Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 497 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Transplantation, Liver Clear all
Terminated Phase 1Phase 2 Interventional Results available

Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC

NCT02013778
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
HCQ
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Sep 15, 2026, 10:50 AM EDT
Completed Not applicable Interventional

Clinical Benefits of B-Flow Ultrasound

NCT02008097
View directory record Official record
Conditions
Evidence of Liver Transplantation, Arterial Occlusive Diseases, Hypertension, Pregnancy, High Risk, Pregnancy
Interventions
GE LOGIQ E9 Ultrasound System
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 100 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Sep 15, 2026, 10:50 AM EDT
Terminated Phase 4 Interventional Results available

Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus

NCT00260208
View directory record Official record
Conditions
Liver Transplant, Hepatitis C
Interventions
Cyclosporine A, Tacrolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Sep 15, 2026, 10:50 AM EDT
Completed Phase 4 Interventional Results available

Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation

NCT00206076
View directory record Official record
Conditions
Liver Disease
Interventions
mycophenolate mofetil
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Lexington, Kentucky • Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Sep 15, 2026, 10:50 AM EDT
Completed Phase 4 Interventional Results available

Single Center Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients

NCT00374231
View directory record Official record
Conditions
Liver Transplantation
Interventions
tacrolimus, mycophenolate mofetil, Prednisone
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Sep 15, 2026, 10:50 AM EDT
Not listed No phase listed Observational

Osteoporosis in Children and Adults Following Liver Transplantation

NCT00008788
View directory record Official record
Conditions
Osteoporosis, Liver Transplantation
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
16 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 15, 2026, 10:50 AM EDT
Completed Phase 1 Interventional

A Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation

NCT01074203
View directory record Official record
Conditions
Hepatitis C Recurrence
Interventions
Nitazoxanide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Sep 15, 2026, 10:50 AM EDT
Completed No phase listed Observational

Impact of Interferon-free Treatment for Hepatitis C Virus (HCV) on Blood Cells and Factors in Blood

NCT02718573
View directory record Official record
Conditions
Hepatitis C, HCV, Liver Transplant
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 15, 2026, 10:50 AM EDT
Terminated Phase 2 Interventional Results available

Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation

NCT01151761
View directory record Official record
Conditions
Cholangiocarcinoma, Hepatobiliary Neoplasm, Liver Cancer, Bile Duct Cancer, Cancer of Gallbladder
Interventions
Stereotactic Body Radiotherapy, Gemcitabine, Cisplatin, Carboplatin, Capecitabine, 5FU, Liver transplantation
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Sep 15, 2026, 10:50 AM EDT
Withdrawn Not applicable Interventional

Feasibility of Use of BariCare App in Pre-transplant Population

NCT01859104
View directory record Official record
Conditions
Obesity, Pre-Renal Transplant Candidate, Pre-liver Transplant Candidate
Interventions
Use of smartphone app
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 15, 2026, 10:50 AM EDT
Completed Not applicable Interventional Results available

Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.

NCT01936519
View directory record Official record
Conditions
Immunosuppression, Renal Failure
Interventions
Arm A: Everolimus, Calcineurin Inhibitor
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 15, 2026, 10:50 AM EDT
Not yet recruiting Not applicable Interventional

Peer Support for Liver Transplant Recipients With History of ALD

NCT07397598
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol Related Liver Disease, Liver Transplant Recipient
Interventions
Peer Support
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 15, 2026, 10:50 AM EDT
Completed No phase listed Observational

POCS in Liver Transplantation Patients

NCT03205072
View directory record Official record
Conditions
Liver Transplant; Complications
Interventions
Spy Glass DS
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Sep 15, 2026, 10:50 AM EDT
Completed Early Phase 1 Interventional

Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation

NCT01909401
View directory record Official record
Conditions
Liver Transplantation
Interventions
boceprevir
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 15, 2026, 10:50 AM EDT
Withdrawn Not applicable Interventional

A Pilot Study of mDOT for Immunosuppressant Adherence in Adult Liver Transplant Recipients

NCT03515330
View directory record Official record
Conditions
Medication Adherence, Liver Transplant
Interventions
mHealth Intervention
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Sep 15, 2026, 10:50 AM EDT
Completed Phase 4 Interventional Results available

LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients

NCT02631772
View directory record Official record
Conditions
Hepatitis C
Interventions
Sofosbuvir/Ledipasvir x 12 weeks, Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Cleveland, Ohio • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 15, 2026, 10:50 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues

NCT01757730
View directory record Official record
Conditions
Heart Failure, Liver Fibrosis, Cardiac Transplant Rejection, Aortic Aneurysms
Interventions
Not listed
Lead sponsor
Arunark Kolipaka
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 15, 2026, 10:50 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

CM for Patients With ALD After Liver Transplant

NCT06304467
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol; Liver, Post Liver Transplant, Contingency Management, Alcohol Liver Disease
Interventions
Contingency Management
Behavioral
Lead sponsor
Arpan A. Patel, MD
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 15, 2026, 10:50 AM EDT
Enrolling by invitation Phase 3 Interventional

Rezafungin Prophylaxis in Liver Transplant

NCT06774144
View directory record Official record
Conditions
Liver Transplant Infection, Fungal Infection
Interventions
Rezafungin, Standard of care antifungal prophylaxis
Drug
Lead sponsor
Fernanda P Silveira, MD, MS
Other
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 15, 2026, 10:50 AM EDT
Not listed Phase 1Phase 2 Interventional

Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis

NCT05006430
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Fecal Microbiota Transplantation, Placebo
Biological · Other
Lead sponsor
Prasun Kumar Jalal
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 15, 2026, 10:50 AM EDT
Terminated Not applicable Interventional Results available

OCS Liver DCD Trial

NCT04194437
View directory record Official record
Conditions
Liver Transplant
Interventions
OCS Liver System
Device
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Boston, Massachusetts • Detroit, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 15, 2026, 10:50 AM EDT
Enrolling by invitation No phase listed Observational

Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant

NCT05224583
View directory record Official record
Conditions
Polyomavirus Infections, BK Viremia, Liver Transplant Infection, Kidney Transplant Infection
Interventions
Simultaneous Liver-Kidney Transplant
Procedure
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Timeline
2021 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 15, 2026, 10:50 AM EDT
Completed Phase 4 Interventional

The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver Transplant

NCT00275639
View directory record Official record
Conditions
Liver Transplant Recipients
Interventions
Cozaar
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Sep 15, 2026, 10:50 AM EDT